Tokyo, Japan – September 2025 – EXORPHIA Inc. (Headquarters: Tokyo, CEO: Koji Kuchiishi) is pleased to announce that Kenichi Tamura, Head of CMC Development, will deliver a presentation at the 7th Exosome-Based Therapeutic Development Summit, taking place from September 23–25, 2025, at The Colonnade Hotel in Boston, USA.
The Exosome-Based Therapeutic Development Summit is a premier international conference where global leaders in extracellular vesicle (EV) therapeutics gather to discuss cutting-edge advances in disease applications, analytical methods, purification technologies, clinical-scale manufacturing, and translational development.
■Presentation Details
- Title: Cracking the Code: Predicting Exosome Pharmacology Through Physicochemical Insights
- Content: Presentation of EXORPHIA’s proprietary manufacturing and quality control strategy, integrating large-scale production data with pharmacological insights to address the “black box” challenges of MSC and EV therapeutics.
- Date & Time: September 23, 2025, 10:00 AM
- Session: Pre-Conference, 7th Exosome-Based Therapeutic Development Summit
- Venue: The Colonnade Hotel, Boston, USA
- Speaker: Kenichi Tamura, Head of CMC Development, EXORPHIA Inc.
For further details, please refer to the conference program [here].
■Media Contact
Public Relations, EXORPHIA Inc.
Email: inquiry@exorphia.com
EXORPHIA will continue to lead international discussions on EV-based therapeutics, advancing the standardization and industrialization of this next-generation modality.
